Kava extract reduces
anxiety-related
distress in
chicks mainly due to its dihydrokavain content, which provides
anxiolytic effects without the
sedation caused by standard drugs like
chlordiazepoxide. Dihydrokavain showed the highest systemic exposure among all six major kavalactones tested, indicating it may play a central role in kava's pharmacological effects in humans. Additionally, intraperitoneal administration of dihydrokavain (150 mg/kg) in
mice produced a significant
analgesic effect. Among the six major kavalactones, it showed the strongest inhibition of
norepinephrine-induced
calcium signaling in
lung cancer cells by antagonizing
β-adrenergic receptors, suggesting its potential role in kava's anxiolytic and
cancer-preventive effects. Dihydrokavain has been shown to inhibit
cyclooxygenase enzymes, reducing
COX-1 activity by approximately 58% and
COX-2 by 28%, suggesting potential
anti-inflammatory effects. It also reduces
TNFα secretion in
lipopolysaccharide-stimulated
THP-1 cells (a human acute monocytic leukemia-derived cell line) at a concentration of 50 μg/mL. In vitro studies show that dihydrokavain inhibits the
cytochrome P450 enzymes
CYP2C9 (IC50 = 130.95 μM),
CYP2C19 (IC50 = 10.05 μM), and
CYP3A4 (IC50 = 78.59 μM), indicating potential
drug interaction risks. Dihydrokavain bears some structural similarity to the
strobilurins and has some
fungicidal activity. An analogue of the molecule, 56DHK, is a compound in
Alpinia mutica and improves hyperglycemia in a diabetic
Drosophila model by activating
AMP-activated protein kinase (AMPK) signaling and modulating related metabolic genes, showing potential as a novel
anti-diabetic agent. ==References==